The Epibase® technology has the capability to predict both Class-I and
Class-II restricted T-cell epitopes present in therapeutic proteins or
antibodies.
Proteins can induce an antibody response (B-cell driven), when both T-helper
epitopes and B-cell epitopes are present. AlgoNomics' Tripole® platform is
optimally suited to alter B-cell epitopes to reduce potential antibody
recognition sites. This application has been recurrently used to humanize
murine therapeutic antibodies. Optimally, this is done in conjunction with
an Epibase® HLA-ClassII profile, to reduce also the T-helper response.

Proteins can induce T-cell responses, even if they are fully human versions.
Many types of antibodies, also when humanized or fully human, can induce
this response. In such a situation the T-cells recognize particular sites of
these proteins or antibodies as non-self, and thereby generate immune
reactions or immunogenic side-effects. AlgoNomics offers the technology to
re-engineer these protein or antibody regions without compromising the
efficacy. By substituting the relevant amino acids of the immunogenic
regions the immunization can be removed.

For specialized applications, T-cell epitopes need to be altered or
enhanced. Here also, the combination of Epibase® and Tripole® technology
lead to a fast identification of alterations to be made to a peptide or
therapeutic protein.